Made with FlowPaper - Flipbook Maker
1 medhealthoutlook.com Biotech Edition OCT 2021 Innovators Medhealth Outlook 2021 BIOTECH CELL ANALYSIS SOLUTIONS THAT ACCELERATE SCIENTIFIC DISCOVERY CYTEK BIOSCIENCES ® Wenbin Jiang Ph.D., CEO3Copyright @202 1 Medhealth Outlook. All Rights Reserved. The content and images used in the publication should not be reproduced or transmitted in any form or by any means without the prior permission of Medhealth Outlook. Monica Philip Joseph Morgan Visualizers editor@medhealthoutlook.com Richard Taylor Dave WalkerSam Morris Editorial staffs Natasha Jacob Managing Editor OCT 2021 Copyright @ Medhealth Outlook 2021 Subscribe medhealthoutlook.com While many sectors struggled during COVID19, the biotech sector has continued to grow and attract strong investment. As of the summer of 2020, 37 biotech companies raised a total of $ 6.7 billion through U.S. IPOs, compared to $ 5 billion in 51 initial public offerings in 2019. The Nasdaq Biotech Index rose to a high of five years in December 2020: an increase of more than 25 percent since the beginning of the year. 4,444 Biotech’s presence in biopharmaceutical research and development (R&D) has also increased in recent years. In 2019, the number of biotech products in process of R&D increased by 14 percent year-on-year: from 4,751 products to 5,422, three times more than in 2009, and between 2018 and 2019 the number of these therapies in process increased by more than 20 percent. Additionally, biotech companies continue to play a leadership role in developing, alone or in collaboration with other stakeholders, COVID19 vaccines or treatments. As biotech companies attract new investment, they must consider how they can scale and what it takes to deliver on their promise to deliver innovative medicines to patients. One of the main reasons for long-term success is creating a portfolio of products for sustainable growth: This research seeks to discover what portfolio approaches have led biotechnology to scalability, innovation for patients, and financial success for investors and founders. It is not enough to plan and implement a path to maturity; The management team of a biotech company must routinely reassess its position and decide when to change course. A clear understanding of the decisions to be made in all dimensions and a plan that corresponds to the profile and ambitions of the company allows the scale trip to be managed successfully. This edition tries to declutter the deadlock situation today’s businesses are grappling and shine light on some of the most tangible solutions for your most crucial bottlenecks. Editors Note The New Dosage of Innovation and Investments Natasha Jacob Managing Editor Sam Morris Sales sam@medhealthoutlook.com sales@medhealthoutlook.comLeading the Charge in Clinical Variant Analysis Powering up the Digital Health GOLDEN HELIX BRIGHTINSIGHT John R. Beaver President & CEO Kal Patel, MD, Co-Founder & CEO, BrightInsight 20 16 CELL ANALYSIS SOLUTIONS THAT ACCELERATE SCIENTIFIC DISCOVERY CYTEK BIOSCIENCES ® Innovators Medhealth Outlook 2021 BIOTECH28 18 22 36 31 DEDICATED DONOR POOLS AND CELL THERAPY SCALABILITY LOOK INTO THE FUTURE OF YOUR BIOTECHNOLOGY FACILITY USING SIMULATIONS THE CONUNDRUM OF COMPLEX SCIENCE AND CONFUSING TERMS WHY DCTS ARE PERFECT FOR SMALL BIOTECHS BIOTECHNOLOGY ARTICLE: HEALTHCARE TECHNOLOGY FOR PATIENTS WITH FEW TECHNOLOGY RESOURCES AND LITTLE TECHNOLOGY TRAINING Contents Abby McDonald, Ph.D., Manager, Solutions Development, Be The Match BioTherapies Niranjan Kulkarni, PhD, Director of Operations Improvement, CRB Jeffrey W. Walker, CEO, Content Carnivores, LLC Curt Kwak, Chief Information Officer at Proliance Surgeons Single Platform for Unmet Medical Needs Biotechnology Accelerating Healthcare PLURISTEM THRIVE BIOSCIENCE Yaky Yanay, CEO Thomas Forest Farb-Horch 30 26 Matty Notaro, Chief Operating Officer at ObvioHealth8 COVER STORY CYTEK BIOSCIENCES ® CELL ANALYSIS SOLUTIONS THAT ACCELERATE SCIENTIFIC DISCOVERY I mmunology—the science and study of the immune system and the body’s system of defense against disease—has been an important field of medical research since 1798, but recent advancements are shedding more light on the physiological functioning of the immune system. While immunology has applications in a wide range of medical fields, cancer and infectious disease research have emerged as two critical areas of study garnering intense interest and investment from the sectors of academia, biotechnology, and pharmaceuticals. Cancer research is constantly evolving, with scientists and clinicians always striving to improve diagnostics and treatment. New approaches that employ the immune system to target and attack disease are advancing the collective understanding and diagnosis of cancer, offering an alternative to the traditional means of treatment. These traditional treatment methods, such as chemotherapy and radiation, are not specifically targeted to the tumor, nor are they specifically tailored to the patients. As a result, these treatments often include harmful side effects that are deteriorative to the body. Immuno‐oncology, on the other hand, uses the 9 Innovators Medhealth Outlook 2021 BIOTECH Wenbin Jiang Ph.D., CEONext >